PYXS Live signals | Maximize Profits with Getagraph.com

SELL 129995 min ago

@ $4.80

Issued: 14 Feb 2024 @ 09:34

Return: -12.47%

Previous signal: Feb 13 - 15:53

Previous signal: Buy

Return: 4.07 %

Live Chart Being Loaded With Signals

Commentary (14 May 2024 @ 16:00):

Stats
Today's Volume	541 735
Average Volume	734 144
Market Cap	247.28M
EPS	$0 ( 2024-05-11 )
Next earnings date	( $-0.250 ) 2024-08-11
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.27
ATR14	$0.00900 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-26	Connealy Pamela Ann	Buy	328 710	Common Stock
2024-03-26	Sullivan Lara	Buy	1 071 242	Stock Option (Right to Buy)
2024-03-26	Flavin John L	Buy	35 219	Common Stock
2024-03-26	Cline Darren S	Buy	35 219	Common Stock
2024-03-26	Lewis-hall Freda C	Buy	35 219	Common Stock

INSIDER POWER
78.71
Last 91 transactions
Buy: 19 296 822 \| Sell: 29 966 464

Volume Correlation

Long: 0.11 (neutral)

Short: 0.53 (weak)

Signal:(32.109) Neutral

Pyxis Oncology, Inc. Correlation

10 Most Positive Correlations
REYN	0.931
MRUS	0.927
YMAB	0.927
CGEM	0.921
RMRM	0.915
KYMR	0.911
IMNM	0.91
SRTS	0.909
SRPT	0.908
GBNY	0.907

10 Most Negative Correlations
CRCT	-0.932
BOCH	-0.929
SHSP	-0.922
VALN	-0.911
SGML	-0.907
VNET	-0.905
VRM	-0.903
CSSEN	-0.902
LHDX	-0.902
CNTY	-0.899

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pyxis Oncology, Inc. Correlation - Currency/Commodity

-0.01
( neutral )

-0.34
( neutral )

0.00
( neutral )

0.07
( neutral )

0.00
( neutral )

-0.59
( weak negative )

Pyxis Oncology, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-2.00M (0.00 %)
EPS:	$-1.850

FY	2023
Revenue:	$0
Gross Profit:	$-2.00M (0.00 %)
EPS:	$-1.850

FY	2022
Revenue:	$0
Gross Profit:	$-1.84M (0.00 %)
EPS:	$-3.57

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-8.95

Financial Reports:

No articles found.

Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.